Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
2006-09-12
2006-09-12
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C530S345000, C530S362000, C530S363000, C530S391100, C530S391300, C530S391500, C530S391700
Reexamination Certificate
active
07105160
ABSTRACT:
Hybrid proteins are described which comprise one or more antigen-binding antibody fragments covalently linked to one or more serum carrier proteins. The hybrid proteins can bind antigens, have a long half-life in vivo and can be used in medicine for therapy and diagnosis.
REFERENCES:
patent: 4749570 (1988-06-01), Poznansky
patent: 4751286 (1988-06-01), Packard et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5714142 (1998-02-01), Blaney et al.
patent: 6350431 (2002-02-01), Snow et al.
patent: WO 92/22583 (1992-12-01), None
patent: WO 93/15199 (1993-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/00171 (1998-01-01), None
Delgado et al. British J. Cancer 73: 175-182, 1996.
K.A. Barr, Pharmaceutical Engineering, Protocol for Efficient Secretion of HSA Developed fromPichia pastoris, 12:48-51, Mar./Apr. 1992.
L. Bartalena, Clinics in Laboratory Medicine, Thyroid Hormone Transport Proteins, 13:583-598, Sep. 1993.
M. Better, International Genetic Engineering, Inc.,Escherichia coliSecretion of an Active Chimeric Antibody Fragment, 240:1041-043, May 1988.
F. Bree, Clinical Pharmacokinetics, Pharmacokinetcs of Intravenously Administered 125I-Labelled Human α1-Acid Glycoprotein, 11:336-342, 1986.
A.P. Chapman, Nature Biotechnology, therapeutic antibody fragments with prolonged in vivo half-lives, 17:780-783, Aug. 1999.
D.J. Chiswell, Tibtech, Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?, 10:80-84, Mar. 1992.
J.M. Cregg, Bio/Technology, Recent advances in the Expression of foreign Genes inPichia pastoris, 11:905-910, Aug. 1993.
R. Fleer, Bio/Technology, Stable Multicopy Vectors For High-Level Secretion of Recombinant Human Serum Albumin by Kluyveromyces Yeasts, 9:968-975, Oct. 1991.
D. Gitlin, Journal of Clinical Investigation, The Selectivity of the Human Placenta in the Transfer of Plasma Proteins from Mother to Fetus, 10:1938-1951, 1964.
A.H. Horwitz, Proceedings of the National Academy of Sciences of the United States of America, Secretion of Functional Antibody and Fab Fragment from Yeast Cells, 85:8678-8682, 1988.
D.R. Hurwitz, Transgenic Research, Specific combinations of human serum albumin introns direct high level expression of albumin in transfected COS cells and in the milk of transgenic mice, 3:365-375, 1994.
J.K. Kim, Eur. J. Immunol, Localization of the site of the murine IgG1 molecule that is involved in binding to the murin intestinal Fc receptor, 24:2429-2434, 1994.
W. Kramer, Nucleic Acids Research, The gapped duplex DNA approach to oligonucleotide-directed mutation construction, 12:9441-9457, 1984.
D. Kraus, Behring Inst. Mitt, Determination of Affinities of Murine and Chimeric Anti-χ/β- T Cell Receptor antibodies by Flow Cytomertry, 87:56-67, 1990.
C. Medesan, The American Association of Immunologists, Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG11, 158:2211-2217, 1997.
M. Nose, Proceedings of the National Academy of Sciences of the United States of America, 80:6632-6636, 1983, Biolog. Sign. of Carbohydrate Chains on Monoclonal Antibodies.
A. A. Ogunjimi, Biotechnology, High-level secretory expression of immunologically active intact antibody from the yeastPichia pastoris, 21:561-567, 1999.
T. Peters, Advances in Protein Chemistry, Serum Albumin, 37:161-245, 1985.
F. Sanger, Proceedings of the National Academy of Sciences of the United States of America, 74:5463-5467, 1977.
D. Sleep, Bio/Technology,Saccharomyces cerevisiaeStrains that Overexpress Heterologous Proteins, 9:183-187, Feb. 1991.
K. Sreekrishna, Gene, Strategies for optimal synthesis and secretion of heterologous protiens in the methylotrophic yeastPichia pastoris, 190:55-62, 1997.
S. Syed, Blood, Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin, 89:3243-3252, May 1997.
M.H. Tao, Journal of Immunology, Studies of Aglycosylated Chimeric Mouse-Human IgG Role of Carbohydrate in the Structure and Effector functions Mediated by the Human IgG Constant Region, 143:2595-2601, Oct. 1989.
T.A. Waldmann, Progr. Allergy, Metabolism of Immunooglobulins, 13:1-110, 1969.
E.J. Wawrzynczak, Molecular Immunology, Blood Clearance in the Rat of a Recombinant Mouse Monoclonal Antibody Lacking the N-Linked Oligosaccharide Side Chains of the CH2 Domains, 29:213-220, 1992.
N. Yukawa, Journal of Immunoassay, Bispecific Rabbit Fab9-Bovine Serum Albumin Conjugate used in Hemagglutination Immunoassay for β-Microseminoprotein, 18:215-233, 1997.
P. Yeh, Proceedings of the National Academy of Sciences of the United States of America, Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum albumin-CD4 Genetic Conjugate, 89;1904-1908, 1992.
Celltech Therapeutics Limited
Chan Christina
DiBrino Marianne
LandOfFree
Antibody-serum protein hybrids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody-serum protein hybrids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody-serum protein hybrids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528712